5-Fluorouracil (5-FU)-based chemotherapy is widely used for the treatment of colorectal cancer (CRC). While optimal doses of 5-FU are generally established based on a patient's estimated body surface area, the plasma concentrations of 5-FU vary among patients. In addition, hyperglycemia in patients with CRC has been reported as a risk factor in poor prognosis. The aim of the present study was to investigate whether hyperglycemia affects antiproliferative effect of 5-FU on the human colon cancer cells (SW480, SW620, LoVo, and HCT116). Growth inhibition of 5-FU was accessed by WST-8 assay. The effect of high glucose (HG, 15 mM) and 5-FU on the cellular proliferation was evaluated by flow cytometry analysis using 5-ethynyl-2′-deoxy-uridine (EdU) incorporation plus 7-AAD. Cell death was determined by flow cytometry using Annexin V-FITC and PI. The results showed that HG, compared to physiological normal glucose (NG) concentration (5 mM), leads to increased cell proliferation and increased GI50 of 5-FU in the four colon cancer cell lines. When the cells were pretreated with a low-dose 5-FU in NG condition, subsequent HG treatment eliminated inhibitory effect of 5-FU in cancer cell growth. In the presence of 5-FU (0.5 μg/mL for LoVo and HCT116; 1 μg/mL for SW480 and SW620), culture with HG for 72 h does not significantly altered cell cycle profile in the four cell lines but significantly increased DNA replication in SW620 (21%) and LoVo (17%). Flow cytometric analysis showed that HG protects cells against 5-FU-induced cell death in SW480. Finally, HG did not alter intracellular level of reactive oxygen species (ROS), although 5-FU indeed induced higher intracellular level of ROS. In conclusion, HG attenuates growth inhibition of 5-FU and our results indicate that decreased cell death and increased DNA replication may account for the attenuating effect of a HG environment on 5-FU-induced tumor growth inhibition.
Get full access to this article
View all access options for this article.
References
1.
BarnesB.R., and ZierathJ.R. (2005). Role of AMP-activated protein kinase in the control of glucose homeostasis. Curr Mol Med, 5, 341–348.
2.
BuckS.B., BradfordJ., GeeK.R., AgnewB.J., ClarkeS.T., and SalicA. (2008). Detection of S-phase cell cycle progression using 5-ethynyl-2′-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2′-deoxyuridine antibodies. Biotechniques, 44, 927–929.
3.
ChungF.Y., HuangM.Y., YehC.S., ChangH.J., ChengT.L., YenL.C., WangJ.Y., and LinS.R. (2009). GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer, 9, 241.
4.
CseresnyesZ., SchwarzU., and GreenC.M. (2009). Analysis of replication factories in human cells by super-resolution light microscopy. BMC Cell Biol, 10, 88.
5.
De AngelisP.M., SvendsrudD.H., KravikK.L., and StokkeT. (2006). Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer, 5, 20.
6.
Di PaoloA., LencioniM., AmatoriF., Di DonatoS., BocciG., OrlandiniC., LastellaM., FedericiF., IannopolloM., FalconeA., RicciS., Del TaccaM., and DanesiR. (2008). 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res, 14, 2749–2755.
7.
DurantonB., HollV., SchneiderY., CarnesecchiS., GosseF., RaulF., and SeilerN. (2003). Polyamine metabolism in primary human colon adenocarcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). Amino Acids, 24, 63–72.
8.
FailliA., LegitimoA., OrsiniG., CastagnaM., SpisniR., MiccoliP., and ConsoliniR. (2013). Antiproliferative effects of 5-fluorouracil and oxaliplatin in colon cancer cell lines: comparison of three different cytotoxicity assays. J Biol Regul Homeost Agents, 27, 275–284.
9.
FloodA., MaiV., PfeifferR., KahleL., RemaleyA.T., LanzaE., and SchatzkinA. (2007). Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology, 133, 1423–1429.
10.
FraileR.J., BakerL.H., BurokerT.R., HorwitzJ., and VaitkeviciusV.K. (1980). Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res, 40, 2223–2228.
11.
FritzV., and FajasL. (2010). Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene, 29, 4369–4377.
12.
GriggsJ.J., ManguP.B., AndersonH., BalabanE.P., DignamJ.J., HryniukW.M., MorrisonV.A., PiniT.M., RunowiczC.D., RosnerG.L., ShayneM., SparreboomA., SuchestonL.E., and LymanG.H. (2012). Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 30, 1553–1561.
13.
GuoX., GoesslE., JinG., Collie-DuguidE.S., CassidyJ., WangW., and O'BrienV. (2008). Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res, 28, 9–14.
14.
JoverR., NguyenT.P., Perez-CarbonellL., ZapaterP., PayaA., AlendaC., RojasE., CubiellaJ., BalaguerF., MorillasJ.D., ClofentJ., BujandaL., ReneJ.M., BessaX., XicolaR.M., Nicolas-PerezD., CastellsA., AndreuM., LlorX., BolandC.R., and GoelA. (2011). 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology, 140, 1174–1181.
15.
JullumstroE., KollindM., LydersenS., and EdnaT.H. (2009). Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol, 48, 361–367.
16.
KlineC.L., SheikhH.S., ScicchitanoA., GingrichR., BeachlerC., FinnbergN.K., LiaoJ., SivikJ., and El-DeiryW.S. (2011). Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther, 12, 557–568.
17.
LiL.H., DongH., ZhaoF., TangJ., ChenX., DingJ., MenH.T., LuoW.X., DuY., GeJ., TanB.X., CaoD., and LiuJ.Y. (2013). The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. Eur J Cancer, 49, 1752–1760.
18.
LongleyD.B., HarkinD.P., and JohnstonP.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330–338.
19.
LuP., WeaverV.M., and WerbZ. (2012). The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol, 196, 395–406.
20.
MasurK., VetterC., HinzA., TomasN., HenrichH., NiggemannB., and ZankerK.S. (2011). Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer, 104, 345–352.
21.
MeyerhardtJ.A., and MayerR.J. (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476–487.
22.
MeyerhardtJ.A., SatoK., NiedzwieckiD., YeC., SaltzL.B., MayerR.J., MowatR.B., WhittomR., HantelA., BensonA., WiglerD.S., VenookA., and FuchsC.S. (2012). Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst, 104, 1702–1711.
23.
MonksA., ScudieroD., SkehanP., ShoemakerR., PaullK., VisticaD., HoseC., LangleyJ., CroniseP., Vaigro-WolffA., et al. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst, 83, 757–766.
24.
NohG.Y., HwangD.Y., ChoiY.H., and LeeY.Y. (2010). Effect of diabetes mellitus on outcomes of colorectal cancer. J Korean Soc Coloproctol, 26, 424–428.
25.
PandeyV., ChaubeB., and BhatM.K. (2011). Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells. J Cell Biochem, 112, 2942–2952.
26.
PetersG.J., LankelmaJ., KokR.M., NoordhuisP., van GroeningenC.J., van der WiltC.L., MeyerS., and PinedoH.M. (1993). Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol, 31, 269–276.
27.
PollakM. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915–928.
28.
SadoffL. (1998). Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled. Am J Clin Oncol, 21, 605–607.
29.
SaifM.W., ChomaA., SalamoneS.J., and ChuE. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst, 101, 1543–1552.
30.
SaigusaS., ToiyamaY., TanakaK., OkugawaY., FujikawaH., MatsushitaK., UchidaK., InoueY., and KusunokiM. (2012). Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today, 42, 460–469.
31.
SargentD.J., MarsoniS., MongesG., ThibodeauS.N., LabiancaR., HamiltonS.R., FrenchA.J., KabatB., FosterN.R., TorriV., RibicC., GrotheyA., MooreM., ZaniboniA., SeitzJ.F., SinicropeF., and GallingerS. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28, 3219–3226.
32.
SeifertP., BakerL.H., ReedM.L., and VaitkeviciusV.K. (1975). Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer, 36, 123–128.
33.
SteinK.B., SnyderC.F., BaroneB.B., YehH.C., PeairsK.S., DerrR.L., WolffA.C., and BrancatiF.L. (2010). Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci, 55, 1839–1851.
34.
Tanaka-NozakiM., OndaM., TanakaN., and KatoS. (2001). Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin Cancer Res, 7, 2783–2787.
35.
TomasN.M., MasurK., PiechaJ.C., NiggemannB., and ZankerK.S. (2012). Akt and phospholipase Cγ are involved in the regulation of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and insulin. BMC Res Notes 5,214.
36.
WarburgO. (1956). On the origin of cancer cells. Science, 123, 309–314.
37.
WlodkowicD., TelfordW., SkommerJ., and DarzynkiewiczZ. (2011). Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol, 103, 55–98.
38.
WolpinB.M., MeyerhardtJ.A., ChanA.T., NgK., ChanJ.A., WuK., PollakM.N., GiovannucciE.L., and FuchsC.S. (2009). Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol, 27, 176–185.
39.
XuJ.M., AzzaritiA., TommasiS., LacalamitaR., ColucciG., JohnstonP.G., ChurchS.W., and ParadisoA. (2002). Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin Colorectal Cancer, 2, 182–188.
40.
YamagishiS., ShimadaH., IshikawaT., FujiiS., TanakaK., MasuiH., YamaguchiS., IchikawaY., TogoS., and IkeH. (2005). Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy. Anticancer Res, 25, 1237–1242.
41.
YoshikawaR., KusunokiM., YanagiH., NodaM., FuruyamaJ.I., YamamuraT., and Hashimoto-TamaokiT. (2001). Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res, 61, 1029–1037.
42.
ZhouJ., ZhouY., YinB., HaoW., ZhaoL., JuW., and BaiC. (2010). 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol Rep, 23, 121–128.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
